Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis.

BACKGROUND Over 4 billion people worldwide are exposed to dietary aflatoxins, which cause liver cancer (hepatocellular carcinoma, HCC) in humans. However, the population attributable risk (PAR) of aflatoxin-related HCC remains unclear. METHODS In our systematic review and meta-analysis of epidemiological studies, summary odds ratios (ORs) of aflatoxin-related HCC with 95% confidence intervals were calculated in HBV+ and HBV- individuals, as well as the general population. We calculated the PAR of aflatoxin-related HCC for each study as well as the combined studies, accounting for HBV status. RESULTS Seventeen studies with 1680 HCC cases and 3052 controls were identified from 479 articles. All eligible studies were conducted in China, Taiwan, or sub-Saharan Africa. The PAR of aflatoxin-related HCC was estimated at 17% (14-19%) overall, and higher in HBV+ (21%) than HBV- (8.8%) populations. If the one study that contributed most to heterogeneity in the analysis is excluded, the summarised OR of HCC with 95% CI is 73.0 (36.0-148.3) from the combined effects of aflatoxin and HBV, 11.3 (6.75-18.9) from HBV only and 6.37 (3.74-10.86) from aflatoxin only. The PAR of aflatoxin-related HCC increases to 23% (21-24%). The PAR has decreased over time in certain Taiwanese and Chinese populations. CONCLUSIONS In high exposure areas, aflatoxin multiplicatively interacts with HBV to induce HCC; reducing aflatoxin exposure to non-detectable levels could reduce HCC cases in high-risk areas by about 23%. The decreasing PAR of aflatoxin-related HCC reflects the benefits of public health interventions to reduce aflatoxin and HBV.

[1]  P. van’t Veer,et al.  Peanut butter intake, GSTM1 genotype and hepatocellular carcinoma: a case–control study in Sudan , 2004, Cancer Causes & Control.

[2]  C. Wild,et al.  Mycotoxins and Human Disease: a Largely Ignored Global Health Issue , 2022 .

[3]  C. J. Chen,et al.  Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. , 1997, Journal of hepatology.

[4]  C. J. Chen,et al.  Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. , 2001, Carcinogenesis.

[5]  Xi-Dai Long,et al.  XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk , 2009, BMC Cancer.

[6]  L. Hedges,et al.  Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.

[7]  Wen-Jen Yang,et al.  Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  Leslie T. Stayner,et al.  IARC Monographs on the evaluation of carcinogenic risks to humans: Some traditional herbal medicines, some mycotoxins, naphthalene and styrene , 2002 .

[9]  Long-yu,et al.  Codon 249 mutation in exon 7 of p53 gene in plasma DNA： maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China , 2003 .

[10]  L W Wang,et al.  Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. , 1996, American journal of human genetics.

[11]  S. Thorgeirsson,et al.  Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China , 2002, Hepatology.

[12]  P. Paul,et al.  Climate change impacts on mycotoxin risks in US maize , 2011 .

[13]  Douglas L. Park,et al.  Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries , 2006, Environmental health perspectives.

[14]  C. J. Chen,et al.  p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. , 1997, Cancer research.

[15]  X. Wang,et al.  Cooperation of tumor‐derived HBx mutants and p53‐249ser mutant in regulating cell proliferation, anchorage‐independent growth and aneuploidy in a telomerase‐immortalized normal human hepatocyte‐derived cell line , 2009, International journal of cancer.

[16]  B. Henderson,et al.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.

[17]  C. Chen,et al.  Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma , 1996, Hepatology.

[18]  Iarc Monographs,et al.  Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. , 2002, IARC monographs on the evaluation of carcinogenic risks to humans.

[19]  M. Heinrich.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene , 2003 .

[20]  B. Henderson,et al.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  Xiao Wang,et al.  A case-control study of risk factors for hepatocellular carcinoma in Henan, China. , 1998, The American journal of tropical medicine and hygiene.

[22]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[23]  L. Darrow,et al.  Confounding and Bias in the Attributable Fraction , 2011, Epidemiology.

[24]  L E Daly,et al.  Confidence limits made easy: interval estimation using a substitution method. , 1998, American journal of epidemiology.

[25]  A. Kuijsten,et al.  Population-Attributable Risk of Dietary Aflatoxins and Hepatitis B Virus Infection with Respect to Hepatocellular Carcinoma , 2004, Nutrition and cancer.

[26]  W. Tsai,et al.  Aflatoxin B1 Exposure, Hepatitis B Virus Infection, and Hepatocellular Carcinoma in Taiwan , 2009, Cancer Epidemiology Biomarkers & Prevention.

[27]  P. Hainaut,et al.  In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. , 2009, Gastroenterology.

[28]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[29]  J. Goedert,et al.  249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma , 2005, Oncogene.

[30]  Chien-Jen Chen,et al.  Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan , 1996, International journal of cancer.

[31]  D. Parkin,et al.  TP53 R249S Mutations, Exposure to Aflatoxin, and Occurrence of Hepatocellular Carcinoma in a Cohort of Chronic Hepatitis B Virus Carriers from Qidong, China , 2009, Cancer Epidemiology Biomarkers & Prevention.

[32]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[33]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[34]  R. Koff,et al.  Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine , 1995 .

[35]  J. Groopman,et al.  Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival , 2011, Molecular carcinogenesis.

[36]  J. Goedert,et al.  Ser-249 p53 Mutations in Plasma DNA of Patients With Hepatocellular Carcinoma From The Gambia. , 2000, Journal of the National Cancer Institute.

[37]  Timothy D Phillips,et al.  Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. , 2004, The American journal of clinical nutrition.